KRASG12C exhibits allele-specific biology in pancreatic cancer and targeting CD24 sensitizes KRASG12C-driven tumors to sotorasib treatment

被引：0
|
作者：
Wei, Yongkun
Liu, Minghui
Nguyen, Phuoc T.
Pan, Dean N.
Yao, Wantong
Ying, Haoqiang
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 02期
关键词：
D O I：
10.1158/1538-7445.PANCA2023-C097
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C097
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Nonclinical Safety Profile of Sotorasib, a KRASG12C-Specific Covalent Inhibitor for the Treatment of KRAS p.G12C-Mutated Cancer
    Ishida, Katsu
    Werner, Jonathan A.
    Davies, Rhian
    Fan, Fan
    Thomas, Barbara
    Wahlstrom, Jan
    Lipford, James Russell
    Monticello, Thomas
    INTERNATIONAL JOURNAL OF TOXICOLOGY, 2021, 40 (05) : 427 - 441
  • [22] Advances in the treatment of KRASG12C mutant non-small cell lung cancer
    Shaverdashvili, Khvaramze
    Burns, Timothy F.
    CANCER, 2025, 131
  • [23] Targeting Krasg12c-mutant cancer with a mutation-specific inhibitor
    Christensen, J. G.
    Olson, P.
    Briere, T.
    Wiel, C.
    Bergo, M. O.
    JOURNAL OF INTERNAL MEDICINE, 2020, 288 (02) : 183 - 191
  • [24] Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
    Torres-Jimenez, Javier
    Espinar, Javier Baena
    de Cabo, Helena Bote
    Berjaga, Maria Zurera
    Esteban-Villarrubia, Jorge
    Fraile, Jon Zugazagoitia
    Paz-Ares, Luis
    DRUGS, 2024, 84 (05) : 527 - 548
  • [25] Aurora A Kinase Inhibition with VIC-1911Potentiates KRASG12C Inhibitor and Overcomes Resistance to Sotorasib in Lung Cancer
    Lee, J. W.
    Kim, S.
    Cruz-Gomez, S.
    Yang, C.
    Burtness, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S48 - S48
  • [26] The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
    Briere, David M.
    Li, Shuai
    Calinisan, Andrew
    Sudhakar, Niranjan
    Aranda, Ruth
    Hargis, Lauren
    Peng, David H.
    Deng, Jiehui
    Engstrom, Lars D.
    Hallin, Jill
    Gatto, Sole
    Fernandez-Banet, Julio
    Pavlicek, Adam
    Wong, Kwok-Kin
    Christensen, James G.
    Olson, Peter
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (06) : 975 - 985
  • [27] Reflections on drug resistance to KRASG12C inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment
    Han, ZhaoYong
    Zhou, Ding
    Wang, JiaMan
    Jiang, Bruce
    Liu, XiYu
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2022, 1877 (01):
  • [28] Synthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug for the Treatment of Cancer
    Chen, Cheng-yi
    Lu, Zhichao
    Scattolin, Thomas
    Chen, Chengsheng
    Gan, Yonghong
    McLaughlin, Mark
    ORGANIC LETTERS, 2023, : 944 - 949
  • [29] Discovery of AMG 510, a first-in-human covalent inhibitor of KRASG12C for the treatment of solid tumors
    Lanman, Brian A.
    Chen, Jian Jeffrey
    Liu, Longbin
    Lopez, Patricia
    Pickrell, Alexander J.
    Reed, Anthony B.
    Wang, Hui-Ling
    Achanta, Pragathi
    Canon, Jude
    Erlanson, Daniel A.
    Fucini, Raymond V.
    Jeong, Joon Won
    Mohr, Christopher
    Saiki, Anne Y.
    Cee, Victor J.
    Lipford, J. Russell
    Rex, Karen
    Volak, Laurie P.
    CANCER RESEARCH, 2019, 79 (13)
  • [30] Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
    Oliver, Timothee
    Haslam, Alyson
    Prasad, Vinay
    TRANSLATIONAL ONCOLOGY, 2023, 28
12345